Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Xenon (XENE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Day One Biopharmaceuticals (DAWN – Research Report) and Xenon (XENE – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Day One Biopharmaceuticals (DAWN)
JonesTrading analyst Soumit Roy maintained a Buy rating on Day One Biopharmaceuticals today and set a price target of $20.00. The company’s shares closed last Monday at $11.70.
According to TipRanks.com, Roy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Day One Biopharmaceuticals with a $22.29 average price target, implying an 89.7% upside from current levels. In a report issued on February 12, Wedbush also reiterated a Buy rating on the stock with a $29.00 price target.
See the top stocks recommended by analysts >>
Xenon (XENE)
In a report released today, Myles Minter from William Blair reiterated a Buy rating on Xenon. The company’s shares closed last Monday at $42.72.
According to TipRanks.com, Minter is a 5-star analyst with an average return of
Xenon has an analyst consensus of Strong Buy, with a price target consensus of $55.56, a 32.1% upside from current levels. In a report issued on February 10, Stifel Nicolaus also maintained a Buy rating on the stock with a $66.00 price target.
